Cognizant's DeepValue Thesis Strengthens After Sell-Off

What happened

Cognizant has been caught in a broad IT services sell-off, pushing its stock to $53.9, down 32% from highs, and now trading at just 11.5x P/E with a net cash balance sheet. The DeepValue master report maintains a POTENTIAL BUY rating, citing solid Q1 revenue of $5.4 billion, strong large-deal bookings (7 deals >$100M), and a TTM book-to-bill of 1.4, which should begin converting into revenue in the second half of 2026 as management's June-July ramp window opens. The 2026 catalyst stack includes the Astreya acquisition closing (AI-managed services), Project Leap restructuring delivering $200-300M in-year savings, and a $2B buyback target that accelerates per-share value. However, risks are real: Project Leap could disrupt delivery, attrition is elevated at 12.3%, and AI pricing transparency may squeeze margins if token metering adoption lags. Despite these risks, the downside is cushioned by net debt of -$326M and a low valuation, making the current entry point around $52-$54 attractive for investors with a 6-12 month view.

Implication

The DeepValue base case of $62 is achievable if large-deal ramps materialize in 2H26 and Project Leap delivers margin expansion, but downside to $45 if restructuring disrupts delivery. Investors should focus on Q3 results for revenue inflection and attrition trends. With net cash and aggressive buybacks, the stock has downside support, but the AI transition introduces uncertainty in unit economics. The bear case is less likely given the balance sheet, but the bull case requires token metering adoption to retain margins. Overall, the risk/reward is favorable at current levels, justifying a potential buy within the $52-$54 entry zone.

Thesis delta

The recent broad IT services sell-off has pushed CTSH to a more attractive entry point near $52-$54, aligning with the DeepValue report's attractive entry zone. The core thesis of large-deal ramps and Project Leap margin expansion remains unchanged, but the lower price reduces downside risk and increases potential upside, making the risk/reward more compelling for patient investors.